MedinCell S.A.
MEDCL.PA · PAR
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.80 | 0.36 | -0.29 | -0.46 |
| FCF Yield | 4.25% | -4.73% | -8.92% | -12.65% |
| EV / EBITDA | -37.39 | -17.01 | -11.30 | -9.67 |
| Quality | ||||
| ROIC | -16.11% | -79.01% | -152.35% | -69.21% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -1.06 | 0.48 | 0.66 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 36.95% | 30.84% | 6.70% | 12.77% |
| Free Cash Flow Growth | 235.78% | 40.48% | 5.59% | -80.13% |
| Safety | ||||
| Net Debt / EBITDA | 0.03 | -2.12 | -1.94 | -1.07 |
| Interest Coverage | -2.13 | -4.54 | -6.11 | -12.91 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 45.80 | 90.57 | 77.19 | 73.09 |